🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

authors.elsevier.com/a/1X8ZV3QE--DP…

Early phase studies associated with significant clinical benefit for cancer patients

Moving forward precision medicine in sarcomas

High-risk localized sarcoma patients deserve neoadjuvant chemotherapy

Updated analysis of the REGOSARC trial. authors.elsevier.com/c/1XCLV3QE--DP…

IFODS 2018: Wonderful talk from Bob Maki about the potential of immunotherapy in sarcomas

Thousands of people celebrating "the wine" in Bordeaux. Fantastic event but missed opportunity to inform about the risks of an overconsumption.

High rate of DDR genes alterations and occurence of BRAF in frame deletions sensitive to MEK inhibition in pancreatic cancer : moving forward precision medicine

2018 Annual meeting of the French Sarcoma Group in Montpellier. Friendly atmosphere, productive collaboration.

1st Molecular Tumor Board of the MULTISARC study. Proud of the team who did an amazing work to make this study feasible. Thanks to INSERM and French Sarcoma Group

Presence of tertiary lymphoid structures as a predictive biomarker of immune-checkpoint inhibitors benefit in sarcomas: moving toward personalized immunotherapy for our patients

Up to 25% of Sarcoma patients have monogenic or polygenic variants in DDR genes. DDR targeting deserves more investigation in this devastating group of diseases.

Molecular profiling results are biased by undersampling. Sequencing of usually discarded tumor material improve the accuracy of molecular data.

Identifying DNA Repair gene mutations beyond BRCA may have a strong clinical impact authors.elsevier.com/a/1b3ea3I2OQUn…

Opening the black box of undifferentiated pleomorphic sarcomas authors.elsevier.com/sd/article/S23…

Nice paper showing the immunomodulatory of PARP7, a new target to improve efficacy of ICI

Fascinating paper investigating the gene expression program of mutation associated neoantigen-specific -TIL in cancer patients treated with ICI. Detectable in a majority of patients (Blood and tissue)

Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance annalsofoncology.org/article/S0923-…

The relentless quest for biomarkers predicting the outcome of immune-checkpoint blockade: 👉in press in Annals of Oncology, plasma proteomics identify Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of resistance annalsofoncology.org/article/S0923-… Gustave Roussy Yohann Loriot

A Cancer Conundrum: Too Many Drug Trials, Too Few Patients nyti.ms/2vsMRXfp an US problem ? In France: not enough drug trials !